Chip stocks fall with Nvidia after data center rev disappointment
Investing.com -- Firefly Neuroscience Inc (NASDAQ:AIFF) stock rose 3% following the announcement of its ongoing collaboration with Heidelberg (ETR:HDDG) University Hospital on a study investigating neurophysiological impacts of 15q13.3 copy number variants.
The AI company, which develops solutions for brain health outcomes, is working with Prof. Dr. med. Christian Schaaf to analyze EEG data from 30 subjects using Firefly’s FDA-cleared technology. The study, scheduled to run through 2026, aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs and characterize neurocognitive profiles linked to deletions versus duplications.
Firefly is commercially engaged to provide EEG systems, training, and analytic support for the research, which builds on previous collaboration between the company and Prof. Schaaf that resulted in a joint publication on CHRNA7-related phenotypes.
"This collaboration reflects our shared commitment to advancing precision neuroscience," said Gil Issachar, Chief Technology Officer of Firefly. The company’s technology will be used to compare study results against its proprietary, FDA-cleared normative database.
Greg Lipschitz, Chief Executive Officer of Firefly, noted increasing industry adoption of the company’s AI-powered technology, stating that pharmaceutical and medical technology organizations are increasingly using objective measures of brain activity like EEG across various stages of product development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.